Inhibikase Therapeutics, Inc. (IKT) vs Nautilus Biotechnolgy, Inc. (NAUT)
A side-by-side comparison of Inhibikase Therapeutics, Inc. and Nautilus Biotechnolgy, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IKT
Inhibikase Therapeutics, Inc.
$2.02HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT
NAUT
Nautilus Biotechnolgy, Inc.
$1.93HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
Total return — IKT vs NAUT
growth of $100 · dividends reinvested · last 6yIKT -96.6% (-43.2%/yr)NAUT -82.7% (-25.4%/yr)NAUT compounded faster over this window
Log scale — wide-divergence pair
IKT NAUT
IKT vs NAUT: by the numbers
- •IKT is the larger company ($266M vs $245M market cap).
- •Both run net losses; IKT's is the smaller (0.00% vs -29747.89% net margin).
Metrics side by side
Valuation
| Metric | IKT | NAUT |
|---|---|---|
| P/S ratio | N/A | 1290.17 |
| P/B ratio | 1.74 | 1.87 |
Profitability
| Metric | IKT | NAUT |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | -29747.89% |
| ROE | -39.55% | -43.11% |
| ROIC | -42.92% | -40.52% |
Growth (annualized)
| Metric | IKT | NAUT |
|---|---|---|
| Total return CAGR (5Y) | -29.10% | -20.56% |
Frequently asked
- How have IKT and NAUT total returns compared?
- Over the past 5 years, IKT delivered -29.10% and NAUT delivered -20.56% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.